Background--Myocardial infarction with nonobstructive coronary arteries (MINOCA) is a heterogeneous disease entity. Its prognosis and predictor of mortality remain unclear. This study aimed to compare the prognosis between MINOCA and myocardial infarction with obstructive coronary artery disease and identify factors related to all-cause death in MINOCA using a nation-wide, multicenter, and prospective registry.
M
yocardial infarction with nonobstructive coronary arteries (MINOCA) is characterized by a positive cardiac biomarker and appropriate clinical scenario consistent with acute myocardial infarction (AMI). MINOCA is an infrequent (5-10% of AMI) syndrome with heterogeneous etiologies, including plaque disruption, coronary spasm, and coronary thromboembolism. Sometimes it is difficult to differentiate it from stress-induced cardiomyopathy, myocarditis, and type 2 myocardial infarction (MI). 1 Accordingly, data regarding the long-term prognosis and its predictors of MINOCA are limited and controversial. Previous studies have demonstrated that MINOCA has a low risk of adverse clinical outcomes. [2] [3] [4] Other studies have reported a considerable rate of mortality in MINOCA compared with MI with obstructive coronary artery disease (MI-CAD). [5] [6] [7] This uncertainty has led to variations in its treatment. Calciumchannel blockers and vasodilators can be used for patients with a positive coronary spasm test. 8 Conventional guidelinerecommended therapies, such as dual antiplatelet therapy, renin-angiotensin system blockers, beta-blockers, and statins, can also be prescribed for patients with MINOCA. 9, 10 Therefore, the objective of this study was to evaluate the long-term risk of clinical outcomes in patients with MINOCA compared with MI-CAD. Independent predictors of mortality, including medications after discharge, were also determined using a large-scale, nation-wide, multicenter, dedicated registry for AMI.
Methods
Anonymized patient-level data will be made available by the corresponding author upon reasonable request.
Study Protocols and Population Selection
Patients were derived from the nation-wide, multicenter, prospective KAMIR-NIH (Korean Acute Myocardial InfarctionNational Institutes of Health) registry. The KAMIR-NIH was a dedicated prospective registry that consecutively enrolled AMI-diagnosed patients at 20 tertiary university hospitals who were eligible for primary percutaneous coronary intervention from November 2011 to December 2015 without any exclusion criteria. The detailed study protocols have been previously published. 11 The protocol of the KAMIR-NIH registry was approved by the ethics committee at each participating center. This study was conducted according to the principles of the Declaration of Helsinki. All patients provided written informed consent upon enrollment. To include the incident AMI patients only, we excluded patients who did not undergo coronary angiography (n=201) and those who had a previous history of MI, coronary intervention, or bypass surgery (n=1636) from 13 104 patients. We enrolled 396 patients with MINOCA (<50% stenosis in all vessels) and 10 871 patients with MI-CAD (≥50% stenosis in any of their coronary arteries). If MINOCA was suspected, a vasospasm test was recommended as a standard of care. Of patients with MINOCA, 95 (24% of MINOCA) demonstrated vasospasm defined by spontaneous coronary spasm with ST-segment elevation (≥0.1 mV) on the coronary angiogram and/or documented coronary spasm during an ergonovine provocation test (Figure 1 ). The test was considered positive for epicardial coronary spasm in the presence of focal or diffuse epicardial coronary diameter reduction ≥90% in comparison with the relaxed state following intracoronary nitroglycerine administration, associated with the reproduction of the patient's symptoms and ischemic electrocardiographic shifts. 12 Data from coronary intravascular imaging or magnetic resonance imaging were limited; we did not include them in this analysis.
Patient Management, Data Collection, and Follow-up
Patient management was performed according to current standard guidelines. Patients with MI-CAD underwent percutaneous coronary intervention by a standard technique if the patient was clinically indicated. Patients were also recommended to take aspirin indefinitely plus P2Y12 inhibitors, renin-angiotensin system blockers, beta-blockers, and statins that were prescribed according to the practice guidelines. Patients with MINOCA were treated with medications under the physician's discretion. Demographic features and cardiovascular risk factors were collected by detailed patient interview. Patient chest pain was categorized according to the presence of substernal chest pain or discomfort that was provoked by exertion or emotional stress and was relieved by rest and/or nitroglycerin. Chest pain was classified as "typical" angina if all 3 descriptors were present and as "atypical" if <3 descriptors were present. During hospitalization, the findings of coronary angiography and detailed procedural characteristics of percutaneous coronary intervention as well as information on the discharge medications were collected. A successful percutaneous coronary intervention was defined as a decrease in minimum stenosis diameter to <30% with Thrombolysis in Myocardial Infarction flow grade ≥2 on coronary angiogram. Recurrent ischemia was defined as presence of angina and changes in
Clinical Perspective
What Is New?
• Patients with Myocardial infarction with nonobstructive coronary arteries (MINOCA) had similar risks of all-cause death and myocardial infarction compared with those with myocardial infarction with obstructive coronary artery disease.
• Risk of all-cause death of MINOCA with vasospasm did not differ from that of MINOCA without vasospasm.
• Use of renin-angiotensin system blockers and statins was independently associated with decreased risk of all-cause mortality in patients with MINOCA.
What Are the Clinical Implications?
• MINOCA is not a benign disease, but a disease which might require clinical attention and intensive medical treatment with renin-angiotensin system blockers and statins to reduce mortality.
hemodynamics or ECG. After discharge, patients were followed at 6, 12, and 24 months by the attending physician. If patients did not visit on the day of the scheduled follow-up, the outcome data were assessed by a telephone interview. All data were collected by independent clinical research coordinators using a web-based case report form in the Internetbased Clinical Research and Trial management system (iCReaT), which is a data management system established by the Centers for Disease Control and Prevention, Ministry of Health and Welfare, Republic of Korea (iCReaT Study No. C110016). Clinical events that occurred within 2 years of follow-up were analyzed.
Primary and Secondary End Points
The primary end point was all-cause death. Secondary end points were cardiac death, noncardiac death, recurrent MI, and repeat revascularization. All deaths were considered cardiac unless an undisputed noncardiac cause was present. Recurrent MI was defined as recurrence of symptoms or presence of electrocardiographic changes in association with a rise in cardiac biomarker level above the upper limit of normal. Periprocedural MI was not included as a clinical outcome. Clinically driven revascularization that occurred after discharge from the index hospitalization was coded as a repeat revascularization event according to the Academic Research Consortium definitions.
Statistical Analysis
Categorical variables were presented as numbers and relative frequencies (percentages). They were compared using the chisquared test. Continuous variables are expressed as meanAESD. They were compared using an independentsample t test. Cumulative event rates were calculated based on Kaplan-Meier censoring estimates. Comparison of clinical outcomes between patients with MINOCA and patients with MI-CAD was performed with a log-rank test. Given that differences in baseline characteristics could significantly affect outcomes, a multivariable Cox regression model was performed, adjusting for confounders as much as possible.
Covariates in the multivariable model were selected if they were significantly different between the 2 groups, including the following: age, sex, Killip class at initial presentation, diabetes mellitus, current smoking, ST changes in the initial ECG, lipid profile, and left ventricular ejection fraction. A propensity score analysis was also performed to adjust for potential confounders with a logistic regression model. The variables listed above were used. Prediction accuracy of the logistic model was assessed with an area under the receiveroperating characteristic curve (C statistic), which was 0.802 (95% CI, 0.780-0.825). According to the propensity score, patients were selected by 1:1 matching without replacement using the nearest neighbor method. A caliper width of 0.2 standardized differences (SD) was used for matching. This value has been shown to eliminate almost 99% of the bias in observed confounders. 13 Furthermore, to identify independent predictors of all-cause death in patients with MINOCA, we used a multivariable Cox proportional hazard model. The C-statistics with 95% CI were calculated to validate the discriminant function of the model. Echocardiogram data of 486 patients (4.3%) was missing: 25 in MINOCA (6.3%) and 461 in MI-CAD (4.2%). We performed the multiple imputation for missing data of the echocardiogram. As a sensitivity analysis, we analyzed data of patients without missing data of echocardiogram (Tables S1 through S3) . In all analyses, participating centers were included as the stratification factor. All probability values were 2-sided, and P<0.05 was considered statistically significant. Statistical packages of SPSS software (version 22.0; SPSS, Inc., Chicago, IL) were used for all statistical analyses.
Results

Baseline Characteristics Between the Groups
Baseline characteristics of the patient groups are listed in Table 1 . Compared with patients with MI-CAD, those with MINOCA were more likely to be women, but less likely to be diabetic. They had a lower Killip class, lower creatine kinasemyocardial band level, lower low-density lipoprotein cholesterol, higher high-density lipoprotein cholesterol, higher Values are n (%) or meanAESD. P value is from a comparison of MINOCA and MI-CAD. BMI indicates body mass index; BP, blood pressure; CABG, coronary artery bypass surgery; CAD, coronary artery disease; CK-MB, creatine kinase-myocardial band; CVA, cerebrovascular accident; DES, drug-eluting stent; HDL-C, high-density lipoprotein cholesterol; LAD, left anterior descending artery; LCX, left circumflex artery; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; MI-CAD, myocardial infarction with obstructive coronary artery disease; MINOCA, myocardial infarction with nonobstructive coronary arteries; PCI, percutaneous coronary intervention; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.
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Journal of the American Heart Association ejection fraction, and lower regional wall motion score in the echocardiogram. However, rates of previous angina and previous heart failure were higher in MINOCA than in MI-CAD.
In-Hospital Events and Medications After Discharge
In-hospital clinical events in patients and medications at discharge and 1 year are summarized in Table 2 . Frequencies of cardiogenic shock and ventricular arrhythmias were lower in patients with MINOCA than in those with MI-CAD during hospitalization. Rate of in-hospital death, recurrent MI, stroke, acute kidney injury, sepsis, or multiorgan failure did not significantly differ between the 2 groups of patients. However, the discharge therapies, including dual antiplatelet therapy, renin-angiotensin system blockers, beta-blockers, and statin, were less frequently used in patients with MINOCA. Use of calcium-channel blockers was higher in patients with MINOCA than that in those with significant stenosis. This trend of the medications was maintained at 12 months after the index hospitalization.
Mid-Term Clinical Outcomes
Results of the comparison of clinical outcomes at 2 years between MINOCA and MI-CAD are shown in Table 3 and Figure 2 . Tables S4 and S5 ). Risk of cardiac death, noncardiac death, or recurrent MI was not significantly different either between the 2 groups. However, risk of repeat revascularization was higher in patients with MI-CAD after multivariate adjustment and propensity matching.
Characteristics and Clinical Results According to Coronary Spasm Test in Patients With MINOCA
Patients with positive vasospasm were younger, more male, and more likely to have typical symptoms, ST elevation on the ECG, low serum creatinine, high ejection fraction, and low regional wall motion index compared with those with MINOCA and negative vasospasm (Table S6 ). The rate of inhospital events was not different between the 2 groups. Most of the patients with positive vasospasm were prescribed calcium-channel blockers whereas dual antiplatelet therapy, renin-angiotensin system blockers, and beta-blockers were used less frequently in patients with positive vasospasm. This trend was also maintained at 12 months after the index hospitalization (Table S7) . Incidence of all-cause death was lower in patients with positive vasospasm than in those with negative vasospasm (3.2% versus 11.0%; P=0.023). There is no difference in occurrence of recurrent MI (4.2% versus 2.3%; P=0.304) and repeat revascularization (3.2% versus 0.7%; P=0.092) between the 2 groups.
Independent Predictors of Mortality in Patients With MINOCA
Multivariable Cox proportional hazard models were used to identify the independent predictors of all-cause death at 2 years in patients with MINOCA ( 
Discussion
In the present study, 2-year clinical outcomes were compared between MINOCA and MI-CAD using data from a nation-wide, multicenter, prospective MI registry. Although patients with MINOCA had lower risk profiles compared with those with MI-CAD, their frequencies of in-hospital events, such as MI, stroke, acute kidney injury, sepsis, and multiorgan failure and rates of mortality and recurrent MI at 2 years, were similar.
For patients with MINOCA, use of renin-angiotensin system blockers and statins showed a significantly lower risk of allcause death.
Previous meta-analyses have demonstrated that patients with MINOCA have a lower likelihood of death or cardiovascular events than those with MI-CAD.
14,15 Baseline characteristics were comparable with previous studies. MINOCA patients of our study also were less likely to be male, diabetic, current smoker, and to be treated with antiplatelet agents, beta-blockers, renin-angiotensin system blockers, and statins. Age and frequency of hypertension in MINOCA patients were higher compared with the previous studies. The results of each of the studies enrolled in the meta-analysis are heterogeneous. Several studies have reported that patients with MINOCA and those with MI-CAD show a similar long-term mortality. 6, 7, [16] [17] [18] The reason for such discrepancies among the studies is likely attributed to the different inclusion criteria because patients with MINOCA have heterogenous mechanistic profiles. In particular, Takostubo syndrome is 1 of the primary mechanisms of MINOCA. 1 Other medical conditions and neurological disorders are critical triggering factors and contribute to the mortality increase in Takostubo syndrome. 19 In the present study, frequency of those conditions in the index hospitalization did not significantly differ between the MINOCA group and the MI-CAD group. A previous study 16 reported that causes of death of MINOCA patients were significantly less often cardiovascular. Though the rate of noncardiac death was numerically higher in patients with MINOCA of previous studies those with MINOCA in this study, it was not statistically significant in every analysis. This suggests that MINOCA patients in this study were more homogenous than those of the other studies.
Elucidating the pathophysiological cause of MINOCA is challenging, but crucial to establish an appropriate management strategy. Coronary spasm and spontaneous coronary dissection (type 2 MI) as well as atherosclerotic plaque disruption and coronary thrombosis (type 1 MI) may be the cause of MINOCA. 20 A provocation test with intracoronary acetylcholine or ergonovine to rule out the vasospasm in MINOCA can be performed safely to identify high-risk patients. 8 In this study, 24% of patients with MINOCA had vasospasm. That rate was comparable with the rate reported in previous studies. 15 The prognosis of patients with MINOCA by vasospasm remains controversial. 8 However, the presence of vasospasm did not influence the risk of all-cause death in the present study. The long-term medical treatment strategy in patients with MINOCA is also a challenging issue. Previous studies have suggested that use of renin-angiotensin system blockers 9, 10 and statins 9 is associated with a lower risk of all-cause death. Our study was in line with those studies. Although one-quarter of the patients had vasospasm, use of calcium-channel blockers was not related to mortality. Use of dual antiplatelet therapy or use of beta-blockers was not an independent predictor of all-cause death either. Because nonobstructive coronary artery lesions cause most MIs, 21 use of reninangiotensin system blockers and statins might be able to suppress the progression of nonobstructive plaques and the occurrence of major cardiac events. Nevertheless, in patients with CAD and absence of heart failure or depressed left ventricular function, renin-angiotensin system blockers has shown beneficial effects on mortality and morbidity. 9 Properly designed and powered randomized clinical trials are needed to confirm this hypothesis. Consistent with a previous study, 22 the present study revealed that nonobstructive coronary artery disease was more common in patients with non-ST elevation MI than that in patients with ST-elevation MI. The present study also showed that ST elevation in MINOCA was associated with an increased risk of all-cause death. This can be explained by more extensive myocardial damage on echocardiography. Female sex also was not the predictor of mortality of MINOCA. Excess risk of post-MI death in women is restricted to those with MI-CAD in previous studies. 14, 23 Furthermore, atypical symptoms was also an independent predictor of allcause death in MINOCA. Compared with typical symptoms, atypical symptoms in MI are related to higher risk profiles of patients and delayed initial management known to be associated with increased mortality. 24 This study had an inherent limitation regarding its observational nature with registry data. However, the KAMIR-NIH registry used standardized definitions for all collected variables regulated and monitored by the National Institutes of Health. In addition, this study did not include information from coronary intravascular imaging or magnetic resonance imaging to reveal all specific causes of AMIs. Stratification by the cause through an in-depth investigation might provide the prognosis and appropriate management strategy according to causes of MINOCA.
Conclusion
Patients with MINOCA have similar risk of all-cause death and MI at 2 years compared with those with MI-CAD. Treatment with renin-angiotensin system blockers and statins might improve the prognosis of these high-risk patients.
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